한국비엔씨

256840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,735-1.80%

2026-09-18

Financials

Valuation Metrics

한국비엔씨's Market Cap is ₩1871B. At end of 2025 it was ₩3064B. Ranked #889 of 2,421 in KR market (top 37%), #421 of 1,640 on KOSDAQ (top 26%), #96 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	187.06B KRW	KR#889/2,421 Sec#96/231
Revenue	91.19B KRW	KR#1,469/2,421 Sec#90/231
Net Income	-6.39B KRW	KR—/2,421 Sec—/231
Total Assets	272.49B KRW	KR#1,096/2,421 Sec#76/231
Net Assets	231.69B KRW	KR#862/2,421 Sec#58/231
Employees	266	KR#884/2,421 Sec#73/231
Value
P/B	0.81x	KR#1,276/2,421 Sec#79/231
P/S	2.05x	KR#1,826/2,421 Sec#104/231
FCF Yield	0.08%	KR#1,212/2,421 Sec#92/231
Profitability
ROE	-2.76%	KR#1,717/2,421 Sec#122/231
ROA	-2.34%	KR#1,781/2,421 Sec#125/231
Op. Margin	-6.15%	KR#1,898/2,421 Sec#125/231
Revenue Growth	-8.21%	KR#1,882/2,421 Sec#176/231
Earnings Growth	-158.08%	KR#1,216/2,421 Sec#79/231
Financial Health
Debt Ratio	17.61%	KR#312/2,421 Sec#44/231
Total Debt	25.00B KRW	KR#1,305/2,421 Sec#104/231
FCF	145.0M KRW	KR#1,214/2,421 Sec#92/231
Cash	92.75B KRW	KR#501/2,421 Sec#25/231
Current Ratio	3.51x	KR#460/2,421 Sec#68/231
Dividend
Div. Yield	2.52%	KR#750/2,421 Sec#38/231
Performance
1Y Return	-46.16%	KR#1,969/2,421 Sec#171/231
1M Return	12.78%	KR#389/2,421 Sec#27/231
From 52W High	-55.74%	KR#1,688/2,421 Sec#128/231
1Y MDD	-64.13%	KR#1,705/2,421 Sec#142/231
Trading
Volume	521,195 shares	KR#223/2,421 Sec#13/231
Trading Value	1.44B KRW	KR#631/2,421 Sec#63/231
Foreign Own.	4.50%	KR#951/2,421 Sec#83/231
Per Share
EPS	-93 KRW	KR—/2,421 Sec—/231
BPS	3,387 KRW	KR#1,776/2,421 Sec#134/231

Company Info

CEO 최완규

Employees 266

Founded 2016

HQ 대구광역시 달서구, KR

Website www.bnckorea.co.kr

동사는 2007년 설립되어 2019년 코스닥시장에 상장한 생체재료 기반 의료기기 전문기업임. 히알루론산과 콜라겐을 가공하여 더말필러, 보툴리눔톡신 등 미용성형용 의료기기, 창상피복재 등 수술시술용 의료기기를 개발 및 생산하며, 생명공학 관련 연구용 시약 및 키트의 바이오유통사업을 영위하고 있음. 세종시에 의약품 GMP 생산시설을 구축하여 보툴리눔톡신 국내품목허가를 획득하는 등 의료기기에서 바이오의약품으로 사업영역을 확장하고 있음. 한국비엔씨는 2016년에 설립되었으며 대구광역시 달서구에 본사를 두고 있습니다.